Sign in
Not yet taking people in United StatesNo phase

PET/MRI of Primary Sclerosing Cholangitis

Key facts

Who runs it
Massachusetts General Hospital
Where
Charlestown, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
10 people, planned
Starts
10 Dec 2026
Expected to end
30 Apr 2029
Type of study
Observational
Treatments tested
  • Radiotracer Injection
  • Contrast Media, Magnetic Resonance
  • Imaging
Record updated
14 October 2026

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Established clinical diagnosis of large duct PSC
  • Participants receiving treatment for IBD are allowed if on a stable dose from screening and expected to remain stable for the duration of the study
  • Serum AST and ALT concentration ≤ 8 times the upper limit of normal

Who cannot take part

  • Subjects whose research-related radiation exposure exceeds current Radiology Department guidelines (i.e., 50 mSv in the prior 12 months)
  • Perioperative liver transplantation period
  • Other causes of chronic liver disease, including secondary sclerosing cholangitis or viral, metabolic, or alcoholic liver disease, as assessed clinically
  • Known or suspected overlapping clinical or histologic diagnosis of autoimmune hepatitis
  • Subjects with electrical implants, such as cardiac pacemakers or perfusion pumps
  • Subjects with ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, prosthetic heart valves that are not compatible with the gradient maps of our scanners, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
  • Subjects with more significant than average potential for cardiac arrest
  • Subjects with a history of major head trauma (i.e., multiple concussions, traumatic brain injury)
  • Subjects with a history of bleeding disorders
  • A history of acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2
  • A history of systemic lupus, multiple myeloma, nephrogenic systemic fibrosis, or other comorbidities resulting in chronic kidney disease stage IV or higher
  • Subjects who anticipate being pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required on the day of the scan before the subject can participate)
  • Subjects less than 18 years of age or greater than 85 years of age
  • Subjects with claustrophobic reactions
  • Subjects unable to lie comfortably on a bed inside the PET/MRI bore as assessed by physical examination and medical history (e.g., back pain, arthritis)
  • Subjects under the direct supervision of the principal investigator
  • Subjects with a body weight of > 300 lbs (operational weight limit of the PET/MRI table) or BMI >33 kg/m2 (the Athinoula A. Martinos Center standard procedure to avoid claustrophobia or mechanical impossibility of fitting the subject into the scanner bore, which is less than 60 cm wide)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical SchoolCharlestown, United StatesContact: Onofrio Catalano, MD, Ph.DNot yet recruiting

About the trial

What the trial wants to find out

This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quantify fibrosis using a novel collagen-binding radiotracer. Specifically, the investigators will be comparing [68Ga]CBP8- and [18F]-FAPI-74 PET/MRI to a liver transient elastography scan in the diagnosis of biliary tree fibrosis.

The group in the trial

  • PSC

    Population will be consecutive patients with PSC, who will be referred to us by the MGB-affiliated hepatologists.

    Treatment: Radiotracer Injection, Contrast Media, Magnetic Resonance, and Imaging

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PET/MRI Evaluation in Patients With Primary Sclerosing Cholangitis Using Intercellular Matrix Radiopharmaceuticals
Criteria questions
Built from NCT06252610, who can take part
Record updated
14 October 2026